These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
447 related articles for article (PubMed ID: 19326431)
1. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Narayanan NK; Nargi D; Randolph C; Narayanan BA Int J Cancer; 2009 Jul; 125(1):1-8. PubMed ID: 19326431 [TBL] [Abstract][Full Text] [Related]
2. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295 [TBL] [Abstract][Full Text] [Related]
3. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373 [TBL] [Abstract][Full Text] [Related]
4. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Zhang W; Zhu J; Efferson CL; Ware C; Tammam J; Angagaw M; Laskey J; Bettano KA; Kasibhatla S; Reilly JF; Sur C; Majumder PK Cancer Res; 2009 Sep; 69(18):7466-72. PubMed ID: 19738074 [TBL] [Abstract][Full Text] [Related]
6. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073 [TBL] [Abstract][Full Text] [Related]
7. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652 [TBL] [Abstract][Full Text] [Related]
8. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer. Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286 [TBL] [Abstract][Full Text] [Related]
9. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Tan M; Xu J; Siddiqui J; Feng F; Sun Y Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. Benitez DA; Pozo-Guisado E; Alvarez-Barrientos A; Fernandez-Salguero PM; Castellón EA J Androl; 2007; 28(2):282-93. PubMed ID: 17050787 [TBL] [Abstract][Full Text] [Related]
11. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Shankar S; Srivastava RK Int J Oncol; 2007 Apr; 30(4):905-18. PubMed ID: 17332930 [TBL] [Abstract][Full Text] [Related]
12. Murine prostate cancer inhibition by dietary phytochemicals--curcumin and phenyethylisothiocyanate. Barve A; Khor TO; Hao X; Keum YS; Yang CS; Reddy B; Kong AN Pharm Res; 2008 Sep; 25(9):2181-9. PubMed ID: 18437538 [TBL] [Abstract][Full Text] [Related]
13. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Hudson TS; Hartle DK; Hursting SD; Nunez NP; Wang TT; Young HA; Arany P; Green JE Cancer Res; 2007 Sep; 67(17):8396-405. PubMed ID: 17804756 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H J Transl Med; 2015 May; 13():150. PubMed ID: 25953027 [TBL] [Abstract][Full Text] [Related]
16. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Wu L; Birle DC; Tannock IF Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283 [TBL] [Abstract][Full Text] [Related]
17. Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor. Guo H; Xu YM; Ye ZQ; Yu JH; Hu XY Pharmazie; 2013 Jun; 68(6):431-4. PubMed ID: 23875250 [TBL] [Abstract][Full Text] [Related]
18. Resveratrol induces cell cycle arrest in human gastric cancer MGC803 cells via the PTEN-regulated PI3K/Akt signaling pathway. Jing X; Cheng W; Wang S; Li P; He L Oncol Rep; 2016 Jan; 35(1):472-8. PubMed ID: 26530632 [TBL] [Abstract][Full Text] [Related]
19. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120 [TBL] [Abstract][Full Text] [Related]